Company news

C4 Therapeutics, Inc. news in 2024

C4 Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

December 7, 2024

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

November 19, 2024

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

November 5, 2024

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

November 4, 2024

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

October 30, 2024

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

October 14, 2024

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

October 8, 2024

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

September 12, 2024

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

September 9, 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

September 7, 2024

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

September 2, 2024

C4 Therapeutics to Participate in Upcoming September Investor Conferences

August 28, 2024

C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation

August 13, 2024

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

July 31, 2024

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

July 15, 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

July 7, 2024

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

June 9, 2024

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 7, 2024

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

April 8, 2024

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

April 7, 2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

March 4, 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

March 3, 2024

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

February 21, 2024

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

January 8, 2024

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

January 3, 2024

Decks in 2024